Finerenone Cuts Heart Failure Events in HFmrEF and HFpEF

FINEARTS-HF establishes the first mineralocorticoid receptor antagonist with a positive pivotal trial in heart failure with mildly reduced or preserved ejection fraction, expanding disease-modifying options beyond SGLT2 inhibitors.

finerenonemineralocorticoid receptor antagonistnonsteroidal MRAHFpEFHFmrEFheart failurehyperkalemiaSGLT2 inhibitorFINEARTS-HFrandomized controlled trialsecondary prevention Cardiology / Anticoagulation

Background Information

Finerenone cuts heart failure events in HFmrEF and HFpEF.

Heart failure with mildly reduced or preserved ejection fraction (HFmrEF and HFpEF) lacks effective treatments, creating a need for new options. The FINEARTS-HF trial showed finerenone reduced worsening heart failure events in patients with a left ventricular ejection fraction of 40 percent or more, compared to placebo (rate ratio, 0.82; P=0.006). Finerenone, a nonsteroidal mineralocorticoid receptor antagonist (MRA), offers a new treatment option for HFmrEF and HFpEF, filling an unmet need despite being a single trial. Finerenone reduces heart failure events in HFmrEF and HFpEF patients.

📊 Deep Analysis Available

Subscribers get the full breakdown: study design, outcomes, pharmacist implications, clinical pearls, GRADE evidence grade, and a downloadable PDF report.

Subscribe for Full Access →

Authors: Solomon SD, McMurray JJV, Vaduganathan M, Claggett B, Jhund PS, Desai AS, Henderson AD, Lam CSP, Pitt B, Senni M, Shah SJ, Voors AA, Zannad F, Abidin IZ, Alcocer-Gamba MA, Atherton JJ, Bauersachs J, Chang-Sheng M, Chiang CE, Chioncel O, Chopra V, Comin-Colet J, Filippatos G, Fonseca C, Gajos G, Goland S, Goncalvesova E, Kang S, Katova T, Kosiborod MN, Latkovskis G, Lee AP, Linssen GCM, Llamas-Esperón G, Mareev V, Martinez FA, Melenovský V, Merkely B, Nodari S, Petrie MC, Saldarriaga CI, Saraiva JFK, Sato N, Schou M, Sharma K, Troughton R, Udell JA, Ukkonen H, Vardeny O, Verma S, von Lewinski D, Voronkov L, Yilmaz MB, Zieroth S, Lay-Flurrie J, van Gameren I, Amarante F, Kolkhof P, Viswanathan P, FINEARTS-HF Committees and Investigators

Citation: Solomon SD, McMurray JJV, Vaduganathan M, et al. Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction. The New England journal of medicine. 2024;391(16):1475-1485. doi:10.1056/NEJMoa2407107

Article Links: PubMed · Journal / DOI

🎓

Reviewed by a licensed pharmacist

Every analysis is reviewed and approved by a licensed pharmacist before publication, ensuring clinical accuracy and relevance.

Accurate and up-to-date information is our highest priority.

If you spot an error, please suggest a correction. If there is a topic you want covered, tell us and we will look at it.

Suggest a correction Request a topic

Full deep analysis for this article is still in progress. Check back soon.